Chicago-Pretreatment testosterone levels correlate with pathologic stagesof prostate cancer and may serve as an independent predictor of extraprostaticdisease in patients initially diagnosed with localized cancers, accordingto a study from the Center for Prostatic Disease Research in Rockville,MD.
Prostate cancer genomic tests show prognostic value for progression, therapy benefit
April 22nd 2024"This preplanned ENACT trial biomarker analysis demonstrates the value of the Decipher score, AR-A score, and PAM50 genomic classifiers in identifying patients undergoing AS who are most likely to benefit from enzalutamide treatment," wrote the authors.